Oct 2 (Reuters) – FDA: * FDA APPROVES LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER- WEBSITE Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Ankur Banerjee SINGAPORE (Reuters) -Asian stocks were poised for solid weekly gains on Friday…
(Reuters) -A multibillion-dollar deal to send Nvidia's artificial-intelligence chips to the United Arab Emirates is…
Oct 3 (Reuters) - Vault Minerals Ltd: * PRELIMINARY Q1 FY26 GOLD SALES WERE 91,477…
(Reuters) -A multibillion-dollar deal to send Nvidia's artificial-intelligence chips to the United Arab Emirates is…
(Reuters) -A multibillion-dollar deal to send Nvidia's artificial-intelligence chips to the United Arab Emirates is…
FIFA's vice president said soccer's global governing body decides whether to move 2026 World Cup…